Have you been hospitalized with diabetic ketoacidosis (DKA) while taking Jardiance, a Type 2 diabetes medication marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly & Company? Jardiance was only approved by the U.S. Food & Drug Administration (FDA) in August 2014, but by May of the following year, it and other sodium glucose co-transporter 2 (SGLT2) inhibitors were being reviewed by the agency because of a possible association with ketoacidosis, a potentially life-threatening condition caused by a build up of toxic ketones (acid) in the blood.
If it is found that Jardiance and other SGLT2 inhibitors increase the risk for ketoacidosis, patients who developed this disorder may be entitled to compensation for their injury-related damages, including any medical bills or lost wages they may have incurred. The nationwide law firm of Bernstein Liebhard LLP is now providing free, no-obligation case reviews to Jardiance patients who were hospitalized following a diagnosis of diabetic ketoacidosis, ketoacidosis, acidosis or ketosis. To learn if you might qualify to file a Jardiance lawsuit, please contact our Firm by calling .
Jardiance (empagliflozin) was approved by the FDA in August 2014 for use in patients with Type 2 diabetes. Glyxambi, a combination of empagliflozin and linagliptin which is also marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly, was approved in February 2015. Jardiance is a once-daily pill that blocks reabsorption of glucose in the kidney, thus increasing glucose excretion and lowering blood glucose levels in adults with Type 2 diabetes. Glyxambi is the first and only Type 2 diabetes treatment available in in the U.S. to combine a SGLT2 inhibitor with a dipeptidyl peptidase-4 (DPP-4) inhibitor in a once-daily tablet.
On May 15, 2015, the FDA announced that it had launched a safety review of Jardiance and other SGLT2 inhibitors, after 20 patients taking the medications had reportedly sought emergency room treatment or been hospitalized with acidosis (reported as diabetic ketoacidosis (DKA), ketoacidosis or ketosis). All 20 cases occurred between March 2013 and June 6, 2014. However, the FDA has continued to receive reports of SGLT2 patients being hospitalized with acidosis since June 2014.
Diabetic ketoacidosis is a serious condition that can lead to diabetic coma or death. According to the FDA, Jardiance patients should be aware of the signs and symptoms of the condition, and seek medical treatment if they experience:
Healthcare providers have been advised to discontinue SGLT2 therapy in Type 2 diabetes patients who have a confirmed diagnosis of diabetic ketoacidosis (DKA), acidosis, ketosis, or ketoacidosis.
If you were diagnosed with diabetic ketoacidosis while using Jardiance, it’s important that you seek the advice of an attorney in order to protect your legal rights. To learn if you might be eligible to file a Jardiance lawsuit, please contact Bernstein Liebhard LLP today, by calling .